Billionaire Paul Allen's foundation is funding a new type of evacuation "cocoon" to help fly sick medical workers from West Africa
If you can't beat them, avoid them.
The Pentagon commits to planning for higher temperatures, and retired generals line up to help
Mobile food startups are moving beyond delivery into food prep
Cities relax or abandon purchasing restrictions in a bid to avoid more serious downturn
Ministry of Supply’s Aviator jacket combines the structure of a tailored garment with the functionality of a windbreaker
The Department of Education may double the number of debt collectors who go after defaulted federal student loans
This year's must-have Silicon Valley office accessory: a $199 bear costume
Santa Clara, Calif.
Founders: Dr. Gerrit Klaerner, Dr. Scott Rocklage, Dr. Detlef Albrecht, and Dr. Jerry Buysse
VC Investment over the last four quarters: $33 million
In October 2007, Relypsa was spun out of Amgen (AMGN) by the founders of a previous biotech startup, Ilypsa, which the biotech company had acquired for $420 million earlier that year. The 47-employee company is developing treatments for hyperkalemia, a potentially deadly condition in patients with heart and kidney disease. By acting in the gastrointestinal tract only, Relypsa's drugs would reduce the risk of side effects that can occur with treatments that are absorbed into the bloodstream.
Key to startup success: "... Intense focus, speed, and efficient use of capital. We have been able to take our lead product program from the initial clinical testing stage in a Phase 1 trial [investigational new drug] to Phase 2 clinical development in nine months, something that most drug discovery and development startups typically achieve ... in three to four years."